Last checked at 18 Oct 2013 07:00
Port Erin Biopharma Investments Limited
(the "Company")
Net Asset Value calculation to 30 September 2013
Jim Mellon, Chairman, commented: -
"The Net Asset Value ("NAV") calculation for the Company as at closing on 30 September 2013 was 17.13 pence per share, including un-invested cash of £742,497 and an accrual of £353,041 for the management fee. The portfolio is valued under IFRS at bid price. This quarter's asset value before management fee represents an increase of 70.9% from the previous valuation of 10.63 pence per share, which included un-invested cash of £707,624. This excellent performance represents increase of 128% over the cash available for investment at inception after listing and operating costs."
| Unaudited to 30 September 2013 £ | |
Fixed Assets |
|
|
| Investments
| 5,434,074 |
Current Assets |
|
|
| Debtors: amounts owing | 9,219 |
| Un-invested cash
| 742,497 |
Current Liabilities |
|
|
| Creditors: amounts due
| (32,049) |
|
| 6,153,741 |
Capital and Reserves |
|
|
| Share Capital | 34 |
| Share Premium | 2,759,551 |
| Current year's earnings | 2,553,790 |
| Retained earnings
| 840,366 |
| 6,153,741 | |
| ||
Shares in Issue
| 33,864,836 | |
Asset Value per share pre management fee | 18.17 pence | |
| ||
Management fee accrual | 353,041 | |
| ||
Net Asset Value per share | 17.13 pence | |
|
--- ENDS ---
Portfolio Details
Investments as at 30 September 2013 | Value | % of Total Portfolio |
Summit Corporation plc |
£1,341,666 |
24.7% |
Plethora Solutions Holdings plc | £968,749 | 17.8% |
Arrowhead Research | £562,557 | 10.4% |
Synergy Pharmaceuticals Inc. | £276,949 | 5.1% |
Ampliphi Biosciences Corp. | £207,319 | 3.8% |
£3,357,243 | 61.8% | |
Aggregate value of remaining holdings below 3% of total portfolio | £2,076,834 | 38.2% |
TOTAL INVESTMENTS | £5,434,074 | 100.0% |
For further information, please contact:
Port Erin Biopharma Investments Ltd | Libertas Capital Corporate Finance Limited | Peterhouse Capital Limited |
The Company | Nomad | Broker |
Denham Eke +44 162 463 9396 | Sandy Jamieson +44 203 697 9495 | Jon Levinson +44 207 469 0935 |